Cambridge Heart Updates Time of Lehman Brothers 9th Annual Global Healthcare Conference Presentation.BEDFORD, Mass. -- As previously announced, Mr. David Chazanovitz, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cambridge Heart, Inc. (OTCBB-CAMH), will present at Lehman Brothers 9th Annual Global Healthcare Conference on Wednesday, March 8, 2006. The presentation is now scheduled for 3:45 PM EST EST electroshock therapy. EST abbr. electroshock therapy . The conference is being held at Loews Miami Beach Hotel from March 8-10, 2006. Mr. Chazanovitz will be discussing recent business highlights including the recent Centers for Medicare and Medicaid Services The Centers for Medicare and Medicaid Services (CMS), previously known as the Health Care Financing Administration (HCFA), is a federal agency within the United States Department of Health and Human Services (DHHS) that administers the Medicare program and (CMS (1) See content management system and color management system. (2) (Conversational Monitor System) Software that provides interactive communications for IBM's VM operating system. ) proposed National Coverage Determination for the company's patented Microvolt microvolt one-millionth (10-6) of a volt; abbreviated µV. T-Wave Alternans technology. The presentation will be webcast and can be accessed on http://customer.talkpoint.com/LEHM002/030806a_cs/ default.asp?entity=Cambridge (Due to its length, this URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) About Cambridge Heart Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the first diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB OTCBB See OTC Bulletin Board (OTCBB). under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com About the Cambridge Heart Microvolt T-Wave Alternans Test The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of, or who are at risk of, life threatening arrhythmias that test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion